Trans-Rectal Ultrasound of the Female Pelvis for Real-Time MRI-US Fusion Based Needle Tracking

Launched by DUKE UNIVERSITY · Jul 28, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to help doctors accurately deliver treatment for uterine cancer using advanced imaging techniques. The study focuses on using a special type of ultrasound called transrectal ultrasound (TRUS) to create detailed images of the female pelvis. These images will be combined with MRI scans to guide doctors as they place treatment needles in the right spots during a procedure known as brachytherapy, which delivers radiation directly to the tumor. The goal is to improve how these treatments are performed, making them safer and more effective.

To participate in this trial, women aged 18 and older who have been diagnosed with certain types of uterine cancer may be eligible, especially if their treatment includes radiation therapy with brachytherapy. However, individuals with active rectal bleeding or ulcers in the rectum cannot participate. If you join the study, you can expect to undergo imaging tests and receive guidance from a new navigation system designed to enhance the precision of your treatment. This study is currently looking for participants, and your involvement could help advance care for other women facing similar challenges.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Histologically proven invasive primary squamous, adenosquamous, or adenocarcinoma of the uterine cervix, (recurrent or medically inoperable) uterine adenocarcinoma.
• • Treatment plan must include curative-intent definitive radiation that includes brachytherapy treatments with or without concurrent chemotherapy
• • Adults ≥ 18 years of age
• • ECOG Performance Status 0-2
• Exclusion Criteria:
• • Patients with active rectal bleeding or rectal ulcer